Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4429607

CCC1CCN(c2ccccn2)CC1.N

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 1/20 0.55
PLD1 Q13393 1/20 0.51
AVPR1A P37288 4/20 0.50
HSD17B10 Q99714 2/20 0.50
GPR119 Q8TDV5 2/20 0.49
SMO Q99835 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26972641 0.89 KDM4E (0.50) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL23875358 0.89 KDM4E (0.50) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL8326977 0.82 PLD1 (0.57) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL1145748 0.82 PLD1 (0.53) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL4764379 0.82 PLD1 (0.53) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL26627827 0.82 PLD1 (0.53) KDM4EALDH1A1MAPTPLD1AVPR1A
SCHEMBL8625320 0.82 KDM4E (0.54) KDM4EALDH1A1MAPTPLD1HSD17B10
SCHEMBL8320670 0.82 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10GPR119
Ammonia Solution, Strong SCHEMBL8126869 0.81 PLD1 (0.56) KDM4EALDH1A1MAPTPLD1AVPR1A
Hydrochloric Acid SCHEMBL121616 0.81 PLD1 (0.51) KDM4EALDH1A1MAPTPLD1AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635775-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7183281-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2007-02-27 US disclosed
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2006-12-28 US disclosed
US-7074783-B2 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-07-11 US disclosed
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK KDM4E 3303/4885ALDH1A1 3104/4885MAPT 4721/4885
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists BDKRB2, BDKRB1, HRH2 KDM4E 3082/4885ALDH1A1 2364/4885MAPT 4735/4885
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK KDM4E 3560/4885ALDH1A1 2366/4885MAPT 4676/4885
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists BDKRB1, BDKRB2, HRH2 KDM4E 3248/4885ALDH1A1 2559/4885MAPT 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.